CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

Journal of Immunology

Volumn 177, Issue 10, 2006, Pages 7398-7405

  Miller, Ashley M ^a   Lundberg, Kajsa ^a   Özenci, Volkan ^a   Banham, Alison H ^b   Hellström, Magnus ^a   Egevad, Lars ^a   Pisa, Pavel ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE; CHEMOKINE CCL22; GLUCOCORTICOID; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN; PROTEIN ICOS; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; GROWTH INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; ASCITES FLUID; CANCER IMMUNOLOGY; CANCER SURGERY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGULATORY T LYMPHOCYTE; SUPERNATANT; TISSUE CULTURE; TISSUE DISTRIBUTION; AGED; ASCITES; BIOSYNTHESIS; BLOOD; CD4 LYMPHOCYTE COUNT; CELL FREE SYSTEM; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AGED; ASCITES; CD4 LYMPHOCYTE COUNT; CELL LINE, TUMOR; CELL-FREE SYSTEM; CHEMOTAXIS, LEUKOCYTE; GROWTH INHIBITORS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 33750807427     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.10.7398     Document Type: Article

References (59)

1. Black, R. J., F. Bray, J. Ferlay, and D. M. Parkin. 1997. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur. J. Cancer. 33: 1075-1107
2. Jemal, A., T. Murray, E. Ward, A. Samuels, R.-C. Tiwari, A. Ghafoor, E. J. Feuer, and M. J. Thun. 2005. Cancer statistics, 2005. CA Cancer J. Clin. 55: 10-30.
3. Arlen, P. M., and J. L. Gulley. 2005. Therapeutic vaccines for prostate cancer: a review of clinical data. Curr. Opin. Invest. Drugs 6: 592-596.
4. Vieweg, J., and J. Dannull. 2005. Technology insight: vaccine therapy for prostate cancer. Nat. Clin. Pract. Urol. 2: 44-51.
5. + immunoregulatory T cells hinder tumor immunotherapy? J. Immunother. 25: 202-206.
6. Dannull, J., Z. Su, D. Rizzieri, B. K. Yang, D. Coleman, D. Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa, and J. Vieweg. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115: 3623-3633.
7. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.
8. O'Garra, A., and P. Vieira. 2004. Regulatory T cells and mechanisms of immune system control. Nat. Med. 10: 801-805.
9. + regulatory T cells. Trends Immunol. 25: 374-380.
10. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323.
11. + effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J. Exp. Med. 197: 181-193.
12. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548.
13. Huang, C. T., C. J. Workman, D. Flies, X. Pan, A. L. Marson, G. Zhou, E. L. Hipkiss, S. Ravi, J. Kowalski, H. I. Levitsky, et al. 2004. Role of LAG-3 in regulatory T cells. Immunity 21: 503-513.
14. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
15. + T regulatory cells. Nat. Immunol. 4: 337-342.
16. + regulatory T cells. J. Exp. Med. 201: 681-686.
17. Houghton, A. N., and J. A. Guevara-Patino. 2004. Immune recognition of self in immunity against cancer. J. Clin. Invest. 114: 468-471.
18. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832.
19. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25: 207-217.
20. high regulatory T cells are ovetrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173: 1444-1453.
21. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099.
22. high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J. Surg. Res. 124: 151-157.
23. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 92: 913-920.
24. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
25. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761.
26. Marshall, N. A., L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, and M. A. Vickers. 2004. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103: 1755-1762.
27. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
28. Ormandy, L. A., T. Hillemann, H. Wedemeyer, M. P. Manns, T. F. Greten, and F. Korangy. 2005. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65: 2457-2464.
29. Unitt, E., S. M. Rushbrook, A. Marshall, S. Davies, P. Gibbs, L. S. Morris, N. Coleman, and G. J. Alexander. 2005. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41: 722-730.
30. Alvaro, T., M. Lejeune, M. T. Salvado, R. Bosch, J. F. Garcia, J. Jaen, A. H. Banham, G. Roncador, C. Montalban, and M. A. Piris. 2005. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11: 1467-1473.
31. Tien, A. H., L. Xu, and C. D. Helgason. 2005. Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res. 65: 2947-2955.
32. Humphrey, P. 2003. Prostate Pathology. American Society Clinical Pathology Press, Chicago, pp. 1-556.
33. Ozenci, V., A. M. Miller, A. Palmborg, L. Egevad, G. A. Jaremko, K. M. Kalkner, and P. Pisa. 2005. Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer. Prostate 65: 20-26.
34. + regulatory T cells at the single-cell level. Eur. J. Immunol 35: 1681-1691.
35. high regulatory cells in human peripheral blood. J. Immunol. 167: 1245-1253.
36. + T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 12: 1145-1155.
37. Yannelli, J. R., C. Hyatt, S. McConnell, K. Hines, L. Jacknin, L. Parker, M. Sanders, and S. A. Rosenberg. 1996. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 65: 413-421.
38. Smith, K. A., and D. A. Cantrell. 1985. Interleukin 2 regulates its own receptors. Proc. Natl. Acad. Sci. USA 82: 864-868.
39. Kalamasz, D., S. A. Long, R. Taniguchi, J. H. Buckner, R. J. Berenson, and M. Bonyhadi. 2004. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. J. Immunother. 27: 405-418.
40. Agnello, D., C. S. Lankford, J. Bream, A. Morinobu, M. Gadina, J. J. O'Shea, and D. M. Frucht. 2003. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J. Clin. Immunol. 23: 147-161.
41. Barton, B. E. 1997. IL-6: insights into novel biological activities. Clin. Immunol. Immunopathol. 85: 16-20.
42. Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190: 995-1004.
43. Chen, M. L., M. J. Pittet, L. Gorelik, R. A. Flavell, R. Weissleder, H. von Boehmer, and K. Khazaie. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl. Acad. Sci. USA 102:419-424.
44. Stravodimos, K., C. Constantinides, T. Manousakas, C. Pavlaki, D. Pantazopoulos, A. Giannopoulos, and C. Dimopoulos. 2000. Immunohistochemical expression of transforming growth factor β1 and nm-23 H1 antioncogene in prostate cancer, divergent correlation with clinicopathological parameters. Anticancer Res. 20: 3823-3828.
45. Kennedy-Smith, A. G., J. L. McKenzie, M. C. Owen, P. J. Davidson, S. Vuckovic, and D. N. Hart. 2002. Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. J. Urol. 168: 741-747.
46. Chan, A. K., D. C. Lockhart, W. von Bernstorff, R. A. Spanjaard, H. G. Joo, T. J. Eberlein, and P. S. Goedegebuure. 1999. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int. J. Cancer 82: 721-726.
47. Bronte, V., T. Kasic, G. Gri, K. Gallana, G. Borsellino, I. Marigo, L. Battistini, M. Iafrate, T. Prayer-Galetti, F. Pagano, and A. Viola. 2005. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J. Exp. Med. 201: 1257-1268.
48. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118.
49. + regulatory T cells. J. Immunol. 174: 2661-2670.
50. + helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res. 65: 1577-1586.
51. + regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 64: 8451-8455.
52. + regulatory T cells. J. Exp. Med. 194: 847-853.
53. Banz, A., C. Pontoux, and M. Papiernik. 2002. Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J. Immunol 169: 750-757.
54. Jonuleit, H., E. Schmitt, K. Steinbrink, and A.H. Enk. 2001. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 22: 394-400.
55. Troy, A., P. Davidson, C. Atkinson, and D. Hart. 1998. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J. Urol. 160: 214-219.
56. Vesalainen, S., P. Lipponen, M. Talja, and K. Syrjanen. 1994. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J Cancer. 30: 1797-1803.
57. Irani, J., J. M. Goujon, E. Ragni, L. Peyrat, J. Hubert, F. Saint, and N. Mottet. 1999. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy: Pathologist Multi Center Study Group. Urology 54: 467-472.
58. McArdle, P. A., K. Canna, D. C. McMillan, A. M. McNicol, R. Campbell, and M. A. Underwood. 2004. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br. J. Cancer 91: 541-543.
59. Shevach, E. M. 2004. Fatal attraction: tumors beckon regulatory T cells. Nat. Med. 10: 900-901.